MedTrace Logo

Antisecretory Factor in Primary Glioblastoma 1

NCT04116138 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-04-28

No results posted yet for this study

Summary

This is a non-randomised, open-label, single center-centre, Phase I-II study in patients with newly diagnosed glioblastoma. 5 patients with newly diagnosed glioblastoma are enrolled in the study and will receive an egg powder enriched for antisecretory factor (AF), Salovum, daily from 2 days before concomitant radio-chemo therapy until 14 days after finalisation.The primary aim of the study is to asses safety and feasibility of this regimen.

Conditions

Interventions

DIETARY_SUPPLEMENT

Salovum

Egg yolk powder enriched for anti secretory factor

Sponsors & Collaborators

  • Region Skane

    collaborator OTHER

  • Lund University

    collaborator OTHER

  • Skane University Hospital

    collaborator OTHER

  • Lantmannen Medical AB

    collaborator OTHER

  • Peter Siesjö

    lead OTHER

Principal Investigators

  • Peter Siesjö, MD, PhD · Skane University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04116138 on ClinicalTrials.gov